Time to initiation of lipid-lowering drugs for subclinical atherosclerosis: sub-study of VIPVIZA randomized controlled trial, with single-arm cross-over

AIMS: Visual information about subclinical atherosclerosis was provided to physicians and participants in the VIPVIZA trial, inclusion 2013–16 in northern Sweden, aiming to improve adherence to cardiovascular disease (CVD) prevention guidelines. Pictorial risk information may be more actionable. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmberg, Henrik, Sjölander, Maria, Glader, Eva-Lotta, Näslund, Ulf, Carlberg, Bo, Norberg, Margareta, Själander, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242024/
https://www.ncbi.nlm.nih.gov/pubmed/35919662
http://dx.doi.org/10.1093/ehjopen/oeac003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242024/
https://www.ncbi.nlm.nih.gov/pubmed/35919662
http://dx.doi.org/10.1093/ehjopen/oeac003

Ejemplares similares